Olymvax Biopharmaceuticals Inc. (SHA: 688319), a leading vaccine specialist headquartered in Chengdu, China, has announced that it has received ethical approval for a Phase I study for its oral recombinant Helicobacter pylori (HP) vaccine (Escherichia coli) in Australia. The company has completed the clinical trial filing for this proprietary product.
Helicobacter pylori, recognized as a Class 1 carcinogen by the World Health Organization, is a significant public health concern. Olymvax Bio has developed a novel approach to combating the infection by screening and isolating antigen proteins that provide robust immune protection. The company has significantly enhanced the bioavailability of these antigens and the immunogenicity of subunit vaccines through the development of innovative oral vaccine formulations and the strategic use of new adjuvants.- Flcube.com
